Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.44 |
| ▸ | GRIK1 | P39086 | 5/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.42 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.42 |
| ▸ | NOS2 | P35228 | 3/20 | 0.41 |
| ▸ | NOS3 | P29474 | 2/20 | 0.41 |
| ▸ | NOS1 | P29475 | 2/20 | 0.41 |
| ▸ | SLC1A2 | P43004 | 6/20 | 0.40 |
| ▸ | SLC1A3 | P43003 | 5/20 | 0.40 |
| ▸ | SLC1A1 | P43005 | 5/20 | 0.40 |
| ▸ | GRIK2 | Q13002 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | GRM8 | O00222 | 1/20 | 0.39 |
| ▸ | GRM6 | O15303 | 1/20 | 0.39 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.39 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.39 |
| ▸ | GSR | P00390 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL890415 | 1.00 | SLC7A5 (0.44) | SLC7A5GRIK1PTGS1SLC7A11NOS2 | |
| Hydrochloric Acid SCHEMBL4408945 | 0.98 | SLC7A5 (0.43) | SLC7A5GRIK1PTGS1SLC7A11NOS2 | |
| Bromide SCHEMBL4412730 | 0.98 | SLC7A5 (0.43) | SLC7A5GRIK1PTGS1SLC7A11NOS2 | |
| Bromide SCHEMBL4412737 | 0.98 | SLC7A5 (0.43) | SLC7A5GRIK1PTGS1SLC7A11NOS2 | |
| Hydrochloric Acid SCHEMBL3870800 | 0.98 | SLC7A5 (0.43) | SLC7A5GRIK1PTGS1SLC7A11NOS2 | |
| SCHEMBL19918392 | 0.86 | SLC7A5 (0.44) | SLC7A5GRIK1PTGS1SLC7A11NOS2 | |
| SCHEMBL1146973 | 0.86 | SLC7A5 (0.44) | SLC7A5GRIK1PTGS1SLC7A11NOS2 | |
| SCHEMBL936382 | 0.86 | SLC7A5 (0.44) | SLC7A5GRIK1PTGS1SLC7A11NOS2 | |
| Hydrochloric Acid SCHEMBL18762600 | 0.84 | SLC7A5 (0.43) | SLC7A5GRIK1PTGS1SLC7A11NOS2 | |
| SCHEMBL18762492 | 0.82 | SLC7A5 (0.41) | SLC7A5GRIK1PTGS1SLC7A11NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171500-A1 | CONFORMATIONALLY STABILIZED RSV PRE-FUSION F PROTEINS | CALDER BIOSCIENCES INC (US) | 2025-05-29 | — | — | US | disclosed |
| US-20250092094-A1 | CONFORMATIONALLY STABILIZED RSV PRE-FUSION F PROTEINS | CALDER BIOSCIENCES INC (US) | 2025-03-20 | — | — | US | disclosed |
| CN-119529036-A | Conformationally stabilized RSV pre-fusion F proteins | 考尔德生物科技有限公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-111405907-B | Conformationally stabilized RSV pre-fusion F proteins | 考尔德生物科技有限公司 | 2024-10-01 | — | — | CN | disclosed |
| US-20240238369-A1 | Conformationally Specific Viral Immunogens | CALDER BIOSCIENCES INC (US) | 2024-07-18 | — | — | US | disclosed |
| US-11993633-B2 | Conformationally stabilized RSV pre-fusion F proteins | CALDER BIOSCIENCES INC (US) | 2024-05-28 | — | — | US | disclosed |
| US-11926649-B2 | Conformationally stabilized RSV pre-fusion F proteins | CALDER BIOSCIENCES INC (US) | 2024-03-12 | — | — | US | disclosed |
| US-11752191-B2 | Conformationally-specific viral immunogens | CALDER BIOSCIENCES INC (US) | 2023-09-12 | — | — | US | disclosed |
| US-20230054569-A1 | COMPOSITIONS AND METHODS FOR TREATING RETINITIS PIGMENTOSA | ALIA THERAPEUTICS SRL (IT) | 2023-02-23 | — | — | US | disclosed |
| US-20230053714-A1 | CONFORMATIONALLY STABILIZED RSV PRE-FUSION F PROTEINS | CALDER BIOSCIENCES INC (US) | 2023-02-23 | — | — | US | disclosed |
| WO-2005019161-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2005-03-03 | — | — | WO | disclosed |
| EP-1482924-A2 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA INC. (CA) | 2004-12-08 | — | — | EP | disclosed |
| EP-1282722-A4 | STABILIZED PROTEINS | AVATAR MEDICAL L L C (US) | 2004-04-07 | — | — | EP | disclosed |
| US-20030232863-A1 | Such as N1-(1-cyanocyclopropyl)-4-fluoro-N2-((1S)-2,2,2-trifluoro-1-(4' -(methylsulfonyl)-1,1'-biphenyl-4-yl) ethyl)-L-leucinamide; for treating osteoporosis and other bone loss disorders | BAYLY CHRISTOPHER I (CA) | 2003-12-18 | — | — | US | disclosed |
| WO-2003075836-A2 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2003-09-18 | — | — | WO | disclosed |
| EP-1282722-A1 | STABILIZED PROTEINS | Avatar Medical, L.L.C. (US) | 2003-02-12 | — | — | EP | disclosed |
| US-20020061549-A1 | Stabilized proteins | CALDER BIOSCIENCES INC. | 2002-05-23 | — | — | US | disclosed |
| WO-2001029247-A1 | STABILIZED PROTEINS | AVATAR MEDICAL, LLC (US) | 2001-04-26 | — | — | WO | disclosed |
| EP-0941233-A2 | ANTIVIRAL PEPTIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1999-09-15 | — | — | EP | disclosed |
| WO-1998022496-A2 | ANTIVIRAL PEPTIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1998-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232863-A1 | Such as N1-(1-cyanocyclopropyl)-4-fluoro-N2-((1S)-2,2,2-trifluoro-1-(4' -(methylsulfonyl)-1,1'-biphenyl-4-yl) ethyl)-L-leucinamide; for treating osteoporosis and other bone loss disorders | CTSE, CTSB, CTSS | SLC7A5 653/4885GRIK1 1182/4885PTGS1 1352/4885 |
| US-20230054569-A1 | COMPOSITIONS AND METHODS FOR TREATING RETINITIS PIGMENTOSA | RHOC, PDE6C, PDE6H | SLC7A5 4453/4885GRIK1 2930/4885PTGS1 1969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.